PFE Trading Analysis - 10/22/2026 04:12 PM — TRU-SENTIMENT

News Headlines & Context

The following items use general knowledge for context only and are separate from the data-driven analysis below:

• Pfizer (PFE) recently advanced multiple oncology pipeline assets into late-stage trials, supporting long-term growth narrative.
• PFE confirmed a quarterly dividend of $1.72 with ex-dividend date of November 6, 2026, a near-term shareholder catalyst.
• Management addressed pricing pressure in legacy vaccines during last earnings call, noting margin stabilization efforts.
• Broad pharma sector benefited from defensive rotation amid macro uncertainty, aligning with PFE's low beta of 0.15.
• No major negative regulatory action reported; sentiment supported by steady volume and options flow.

Context: Headlines suggest stability and income appeal, which loosely supports the bullish options sentiment in the embedded data, though technicals show extended conditions.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data:

• Trailing P/E is 39.60 with trailing EPS of 0.76; valuation appears elevated versus typical large-pharma peers.
• Dividend yield 5.71% (rate 1.72, ex-date 2026-11-06) provides income support; market cap $173.07B.
• Beta 0.15 indicates very low volatility vs market; 52-week range $23.62 to $30.25 (current near high).
• Institutional ownership 44.41%; average volume 29.98M vs recent daily ~19.59M (20d avg from indicators).
• PEG, forward P/E, P/B, revenue, margins, ROE, D/E, FCF all null – no growth/quality metrics available.
• Analyst target and recommendation null – no consensus context in data.
• Fundamentals show defensive income profile; align with bullish sentiment but diverge from overbought RSI 70.72.

Current Market Position

Minute bars (2026-10-21 09:30 to 2026-10-22 15:45) show open 30.00, low 29.86 first bar, closing 29.93; last bar 2026-10-22 15:45 close 30.37 after intraday high 30.44. Daily history: 2026-10-20 close 30.17, 2026-10-21 close 29.87 (volume 13.61M). Current price per indicators: 29.87. Recent action: rally from 27.45 (2026-10-05) to 30.25 high (2026-10-20), pullback to 29.87.

Key levels from data: 30-day high 30.25, low 27.12; Bollinger upper 30.16, lower 27.08; 50-day SMA 28.15. Intraday momentum positive late 2026-10-22 (30.38 to 30.44 then 30.37).

Technical Analysis

SMA alignment: 5 > 20 > 50 (29.72 > 28.62 > 28.15) – bullish stack, no bear cross. RSI 70.72 overbought; MACD positive histogram 0.11 bullish but narrow. Price 29.87 above BB middle 28.62, near upper 30.16 (upper breach risk). 30-day range: price at 89% of range (29.87 vs 27.12–30.25).

True Sentiment Analysis (Delta 40-60 Options)

Options flow (2026-10-22 16:12) shows Bullish:

Call Volume: $2,238,237 (85.5%) Put Volume: $380,758 (14.5%) Total: $2,618,995

Call contracts 17,173 vs put 2,403; 54 of 766 options analyzed (7.0% filter). Pure directional conviction strongly bullish. Divergence: options bullish but spread engine flagged "technicals show no clear direction" (RSI overbought, MACD thin). Near-term expectation: upward bias via calls.

Key Price Levels (Observational Only)